SOPHiA GENETICS

About SOPHiA GENETICS

Financials

Dated, source-cited figures. Estimates are marked.

Products by SOPHiA GENETICS

All products by SOPHiA GENETICS reviewed by our AI panel of experts.

Sophia GeneticsAI Healthcare

AI-powered genomic analysis for clinical and research decisions

Free7.5/10

How Our Review Panel Scores SOPHiA GENETICS

Six independent reviewer personalities assessed SOPHiA GENETICS's product on their own terms. They disagreed by 1.1 points — The Skeptic was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who SOPHiA GENETICS competes with, and how they differ.

Tempus AI, Inc.6.9/10

Tempus AI runs its own centralized CLIA-certified lab, combining genomic sequencing with real-world clinical data and an AI platform for precision oncology, monetizing through in-house diagnostic tests and biopharma data partnerships (NASDAQ: TEM) — versus SOPHiA GENETICS' decentralized SaaS model licensed to hospitals running their own labs.

1 product reviewed on TopReviewed

Q

QIAGEN (QCI Interpret)

QIAGEN's QCI Interpret is a variant-interpretation and clinical-reporting platform sold as part of QIAGEN's broader NGS panel and bioinformatics ecosystem, often bundled with QIAGEN's own sequencing reagents, whereas SOPHiA GENETICS is instrument-agnostic and monetizes via a decentralized, cross-institution data network.

Company Timeline

Key milestones in SOPHiA GENETICS's history, with sources.

1. Aug 4, 2026Partnership

   Collaboration with AstraZeneca on oncology companion diagnostics

   SOPHiA GENETICS entered a collaboration with AstraZeneca to develop and deploy two companion diagnostic tests for precision cancer therapies, one for solid tumors and one for blood cancers.

   prnewswire.com
2. Jun 4, 2026Partnership

   MOU with Memorial Sloan Kettering Cancer Center

   SOPHiA GENETICS signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to build a joint precision-oncology hub combining MSK's clinical diagnostics expertise with SOPHiA's AI platform.

   prnewswire.com
3. Jan 7, 2026Partnership

   Strategic collaboration with MD Anderson Cancer Center

   SOPHiA GENETICS and MD Anderson Cancer Center announced a strategic collaboration combining SOPHiA's AI analytics platform with MD Anderson's clinical expertise to develop advanced sequencing tests for cancer diagnosis and treatment.

   prnewswire.com
4. Oct 16, 2025Launch

   Launched SOPHiA DDM Digital Twins

   SOPHiA GENETICS launched SOPHiA DDM Digital Twins, an AI-powered research tool that generates virtual patient models to help oncologists simulate treatment outcomes.

   prnewswire.com
5. Sep 23, 2025Partnership

   Companion diagnostic partnership with Myriad Genetics

   SOPHiA GENETICS partnered with Myriad Genetics to develop and commercialize a global liquid biopsy companion diagnostic test, combining Myriad's U.S. lab capabilities with SOPHiA's network of 800+ connected institutions in 70+ countries.

   prnewswire.com
6. Jul 23, 2021Funding

   IPO on Nasdaq (SOPH) — $234M raised

   SOPHiA GENETICS completed its initial public offering on the Nasdaq Global Select Market under ticker SOPH, selling 13 million shares at $18 each to raise $234 million.

   startupticker.ch
7. Oct 1, 2020Funding

   Series F — $110M co-led by aMoon and Hitachi Ventures

   SOPHiA GENETICS raised $110 million in an oversubscribed Series F round co-led by aMoon and Hitachi Ventures, with participation from Credit Suisse, Pictet Group, and existing investors.

   prnewswire.com
8. Jan 4, 2019Funding

   $77M round led by Generation Investment Management

   SOPHiA GENETICS raised $77 million in a round led by Generation Investment Management with Idinvest Partners, bringing cumulative funding to $140 million.

   prnewswire.com
9. Jun 18, 2018Acquisition

   Acquired Interactive Biosoftware (Alamut suite)

   SOPHiA GENETICS acquired France-based Interactive Biosoftware, adding its Alamut clinical genomics decision-support suite (Alamut Batch, Focus, and Visual) for an undisclosed price.

   insideprecisionmedicine.com
10. Sep 13, 2017Funding

    Series D — $30M led by Balderton Capital

    SOPHiA GENETICS raised $30 million in Series D funding led by Balderton Capital, with 360° Capital Partners, Invoke Capital, and Alychlo participating.

    prnewswire.com
11. 2014Launch

    Launched first SOPHiA DDM platform application

    SOPHiA GENETICS launched the first application of its SOPHiA DDM platform, analyzing next-generation sequencing data for cancer diagnosis.

    sec.gov
12. Mar 18, 2011Founded

    Incorporated as SOPHiA GENETICS SA

    SOPHiA GENETICS SA was incorporated as a Swiss stock corporation (societe anonyme) in Rolle, Switzerland.

    sec.gov